RTNS 2012
Recent articles
Better tools needed to assess clinical trials
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
Better tools needed to assess clinical trials
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
Trials and tribulations
Clinical trials for fragile X drugs should include a behavioral therapy component, says a parent of a child with the disorder.
Trials and tribulations
Clinical trials for fragile X drugs should include a behavioral therapy component, says a parent of a child with the disorder.
Compensatory mechanisms
Identifying genetic and other factors that protect children at risk of autism from developing the disorder could provide new avenues for treatment.
Compensatory mechanisms
Identifying genetic and other factors that protect children at risk of autism from developing the disorder could provide new avenues for treatment.
Debate over quality of adult-derived stem cells rages on
As the use of induced pluripotent stem cells grows, researchers are searching for ways to make them behave more predictably.
Debate over quality of adult-derived stem cells rages on
As the use of induced pluripotent stem cells grows, researchers are searching for ways to make them behave more predictably.
Complex case
Multiple levels of complexity make it challenging to develop drugs to treat autism.
Complex case
Multiple levels of complexity make it challenging to develop drugs to treat autism.
Fast-forward
In the last three years, autism researchers have gone from sequencing single genes to whole exomes, as highlighted at the Translational Neuroscience Symposium in Switzerland last week.
Fast-forward
In the last three years, autism researchers have gone from sequencing single genes to whole exomes, as highlighted at the Translational Neuroscience Symposium in Switzerland last week.
Explore more from The Transmitter
Breaking the jar: Why NeuroAI needs embodiment
Brain function is inexorably shaped by the body. Embracing this fact will benefit computational models of real brain function, as well as the design of artificial neural networks.
Breaking the jar: Why NeuroAI needs embodiment
Brain function is inexorably shaped by the body. Embracing this fact will benefit computational models of real brain function, as well as the design of artificial neural networks.
Quantifying funding sources across neuroscience labs
We want to hear from you about the sources of funding for your research.
Quantifying funding sources across neuroscience labs
We want to hear from you about the sources of funding for your research.
What kinds of support do early-career researchers need?
Help The Transmitter and Neuromatch bolster the next generation of neuroscientists.
What kinds of support do early-career researchers need?
Help The Transmitter and Neuromatch bolster the next generation of neuroscientists.